{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:44:36Z","timestamp":1793724276856,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1136\/ijgc-2020-002256","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T12:50:46Z","timestamp":1613393446000},"page":"907-913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct04159155","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01367002","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Amy","family":"Jamieson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily F","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Huvila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Blake","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-002256_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.5858\/arpa.2015-0220-OA","article-title":"Interobserver variability in the diagnosis of uterine high-grade endometrioid carcinoma","volume":"140","author":"Thomas","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1136\/ijgc-2020-002256_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1136\/ijgc-2020-002256_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-002256_bb0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of promise: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-002256_bb0040","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the promise molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0050","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002256_bb0055","author":"Committee on the Review of Omics-Based Tests for Prediciting Patient Outcomes in Clinical Trials","year":"2012"},{"key":"10.1136\/ijgc-2020-002256_bb0060","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"P53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0065","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of p53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0070","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0075","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0080","article-title":"Equivalent survival of p53 mutated endometrial endometrioid carcinoma grade 3 and endometrial serous carcinoma","author":"Brett","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0085","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1136\/ijgc-2020-002256_bb0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0095","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0100","first-page":"A3","article-title":"Refining pathologic interpretation of endometrial carcinomas: lessons learned from a nationwide study in a new era of molecular classification","volume":"30","author":"Thompson","year":"2020","journal-title":"Int J Gynecol Caner"},{"key":"10.1136\/ijgc-2020-002256_bb0105","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41379-019-0220-1","article-title":"Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma","volume":"32","author":"Yano","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0110","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG Oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0115","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2019.06.016","article-title":"Comprehensive genomic profiling of recurrent endometrial cancer: implications for selection of systemic therapy","volume":"154","author":"Prendergast","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/path.4056","article-title":"Use of mutation profiles to refine the classification of endometrial carcinomas","volume":"228","author":"McConechy","year":"2012","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0125","article-title":"Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis","author":"Huvila","year":"2020","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0130","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0046-8177(95)90204-X","article-title":"P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis","volume":"26","author":"Sherman","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0135","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classifcation of the PORTEC-3 trial for high-risk endometrial cancer: Imact on prognosis and benefit from adjuvant therapy","volume":"29","author":"Leon-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1136\/ijgc-2020-002256_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1136\/ijgc-2020-002256_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2018.10.019","article-title":"Cancer susceptibility gene mutations in type I and II endometrial cancer","volume":"152","author":"Long","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0155","author":"Fehniger","year":"2020","journal-title":"BRCA1\/2 somatic mutations in patients with advanced or recurrent endometrial cancer"},{"key":"10.1136\/ijgc-2020-002256_bb0160","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002256_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2018.10.032","article-title":"Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression","volume":"152","author":"Ashley","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2020.08.012","article-title":"Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: a case for homologous recombination deficiency testing in uterine serous carcinoma","volume":"159","author":"Wallbillich","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/modpathol.3800006","article-title":"Analysis of HER-2\/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2\/neu, p53 and Ki-67 protein expression, and outcome","volume":"17","author":"Peir\u00f3","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2020-002256_bb0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0185","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0190","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2\/neu: updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002256_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010044","article-title":"Her2 status in high-risk endometrial cancers (PORTEC-3): relationship with Histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers"},{"key":"10.1136\/ijgc-2020-002256_bb0200","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0205","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002256_bb0210","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-17-0520","article-title":"Molecular pathways: targeting the protein kinase Wee1 in cancer","volume":"23","author":"Geenen","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002256_bb0215","article-title":"A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma","author":"Liu","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0220","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0225","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2266","article-title":"LBA36 safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from garnet","volume":"31","author":"Oaknin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0235","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002256_bb0240","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002256_bb0245","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1158\/2326-6066.CIR-20-0149","article-title":"Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer","volume":"8","author":"Horeweg","year":"2020","journal-title":"Cancer Immunol Res"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24004213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24004213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-002256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:38:49Z","timestamp":1753223929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24004213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1048891X24004213"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-002256","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-002256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}